| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer DAE Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... Cancer discovery 4 (9), 1046-1061, 2014 | 2285 | 2014 |
| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation K Takezawa, V Pirazzoli, ME Arcila, CA Nebhan, X Song, E de Stanchina, ... Cancer discovery 2 (10), 922-933, 2012 | 776 | 2012 |
| Immune-checkpoint inhibitors: long-term implications of toxicity DB Johnson, CA Nebhan, JJ Moslehi, JM Balko Nature Reviews Clinical Oncology 19 (4), 254-267, 2022 | 713 | 2022 |
| N-wasp and the arp2/3 complex are critical regulators of actin in the development of dendritic spines and synapses AM Wegner, CA Nebhan, L Hu, D Majumdar, KM Meier, AM Weaver, ... Journal of Biological Chemistry 283 (23), 15912-15920, 2008 | 304 | 2008 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4: 1046–1061. doi: 10.1158/2159-8290 DA Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... CD-14-0337.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 135 | |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 122 | 2021 |
| Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1 V Pirazzoli, C Nebhan, X Song, A Wurtz, Z Walther, G Cai, Z Zhao, P Jia, ... Cell reports 7 (4), 999-1008, 2014 | 86 | 2014 |
| Clinical models to define response and survival with anti–PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma I Pires da Silva, T Ahmed, JL McQuade, CA Nebhan, JJ Park, JM Versluis, ... Journal of Clinical Oncology 40 (10), 1068-1080, 2022 | 71 | 2022 |
| An APPL1/Akt signaling complex regulates dendritic spine and synapse formation in hippocampal neurons D Majumdar, CA Nebhan, L Hu, B Anderson, DJ Webb Molecular and Cellular Neuroscience 46 (3), 633-644, 2011 | 55 | 2011 |
| Vasodilator-stimulated phosphoprotein (VASP) induces actin assembly in dendritic spines to promote their development and potentiate synaptic strength WH Lin, CA Nebhan, BR Anderson, DJ Webb Journal of Biological Chemistry 285 (46), 36010-36020, 2010 | 53 | 2010 |
| Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy SK Wong, CA Nebhan, DB Johnson Frontiers in Immunology 12, 786046, 2021 | 42 | 2021 |
| Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer CB Meador, H Jin, E de Stanchina, CA Nebhan, V Pirazzoli, L Wang, P Lu, ... Molecular cancer therapeutics 14 (2), 542-552, 2015 | 39 | 2015 |
| Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study CA Nebhan, DB Johnson, RJ Sullivan, RN Amaria, KT Flaherty, ... The Oncologist 26 (9), 731-e1498, 2021 | 38 | 2021 |
| Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors M Dankner, Y Wang, R Fazelzad, B Johnson, CA Nebhan, I Dagogo-Jack, ... JCO Precision Oncology 6, e2200107, 2022 | 35 | 2022 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 32 | 2023 |
| Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade C Yan, N Saleh, J Yang, CA Nebhan, AE Vilgelm, EP Reddy, JT Roland, ... Molecular cancer 20, 1-21, 2021 | 29 | 2021 |
| Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition RL Shattuck-Brandt, SC Chen, E Murray, CA Johnson, H Crandall, ... Clinical Cancer Research 26 (14), 3803-3818, 2020 | 29 | 2020 |
| Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M … D Cross, S Ashton, C Nebhan, C Eberlein, MRV Finlay, G Hughes, ... Molecular Cancer Therapeutics 12 (11_Supplement), A109-A109, 2013 | 26 | 2013 |
| 2014 DA Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler 4 10, 1158, 2016 | 21 | 2016 |
| Predictive biomarkers of response to immune checkpoint inhibitors in melanoma CA Nebhan, DB Johnson Expert review of anticancer therapy 20 (2), 137-145, 2020 | 20 | 2020 |
